cas 106635-86-3|| where to buy 2,6-Dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-amine

Produktname:2,6-Dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)quinolin-8-amine

IUPAC Name:2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-amine

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM224514-100mg	in stock	œǠȤƐ
CM224514-500mg	in stock	Ȥǆœƚ
CM224514-1g	in stock	Ȥƴƴȅ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 106635-86-3 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:106635-86-3; Molekulare Formel:C19H17F3N2O3; Schmelzpunkt:-; SMILES-Code:NC1=C2N=C(OC)C=C(C)C2=C(OC3=CC=CC(C(F)(F)F)=C3)C(OC)=C1; Dichte:

: Katalognummer:CM224514; Molekulargewicht:378.35; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Quinolines; Quinolines are an important class of biologically active heterocyclic compounds, and their derivatives usually exhibit a variety of biological activities. They can be used as antimalarial drugs and in the preparation of other antimalarial drugs. Other important activities of quinoline derivatives include inhibitory activity against EGFR-TK and antipsychotic activity. Futhermore, quinoline scaffolds are present in various drug molecules, including the antimalarial drugs aablaquine, chloroquine, mefloquine and primaquine, and the antibacterial agents gatifloxacin, levofloxacin, and moxifloxacin.; Quinoline Price; if you have any question on quinoline price, we will give the professional answers to your short questions.

: Tafenoquine; 60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world’s first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients. The FDA has granted its investigational tafenoquine candidate orphan drug designation for the treatment of patients with acute babesiosis.
Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA and in Australia as KODATEF. It is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older.